Morgan Stanley overweight on Biocon, sees significant upside from its biosimilar pipeline

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Global research firm Morgan Stanley has initiated an overweight call on Biocon with a target at Rs 785 per share. The house is of the view that H2 seems to be strong for the company and Mylan with monetisation prospects of biosimilar pipeline improving. The firm expects significant upside from its biosimilar pipeline in 2019-2021.

Biocon expects its partner Mylan to launch insulin glargine across various markets in Europe in the second half of 2018. The company didn't specify the Australian launch but said it will happen later this year.

Siddharth Mittal, President - Finance of Biocon said that the approval of Mylan and Biocon’s biosimilar Insulin Glargine, Semglee, by the European Commission is significant as it is the first biosimilar approval in EU from our joint portfolio. It comes close on the heels of Ogivri, our biosimilar Trastuzumab, being the first biosimilar from Mylan and Biocon’s joint portfolio to be approved in the US.

Also, Biocon partner Mylan has entered into a pact with Fujifilm to commercialise Humira biosimilar in Europe. Mylan said its partner Biocon will receive economic benefit through this collaboration.

Under the terms of the agreement between the two companies, Fujifilm grants Mylan an exclusive license to commercialise the adalimumab biosimilar in Europe and will receive an up-front fee.

At 09:44 hrs Biocon was quoting at Rs 620.35, up Rs 0.70, or 0.11 percent. It has touched an intraday high of Rs 628.90 and an intraday low of Rs 619.00. The share touched its 52-week high Rs 1,044.40 and 52-week low Rs 294.97 on 13 June, 2017 and 25 May, 2017, respectively.